Analyst Mitchell Kapoor from H.C. Wainwright reiterated a Sell rating on Sarepta Therapeutics (SRPT – Research Report) and decreased the price ...

Sarepta Therapeutics (SRPT – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Kostas ...

A broad licensing and research alliance will hand Sarepta four clinical-stage candidates, while Arrowhead receives $500 ...

Arrowhead Pharmaceuticals' stock rallied 17% due to significant pipeline developments and strategic partnerships. Learn more ...

Arrowhead has entered a worldwide licensing and partnership agreement with Sarepta Therapeutics for rare genetic disease ...

Commerce Bank boosted its stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Free Report) by 15.7% in the 3rd quarter, ...

Arrowhead Pharmaceuticals (ARWR) has secured a new partnership with Sarepta Therapeutics (SRPT). Under the terms of the deal, ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards ...

Learn more about whether BioMarin Pharmaceutical Inc. or Exact Sciences Corporation is a better investment based on AAII's A+ ...

Shares of Sarepta Therapeutics SRPT have soared 43% year to date, significantly outperforming the industry’s 6.9% decline.

Analysts at HC Wainwright issued their FY2024 EPS estimates for Sarepta Therapeutics in a research note issued to investors ...